BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16615426)

  • 1. A case of non-hodgkin's lymphoma of the ovary: usefulness of 18F-FDG PET for staging and assessment of the therapeutic response.
    Komoto D; Nishiyama Y; Yamamoto Y; Monden T; Sasakawa Y; Toyama Y; Satoh K; Ohno M; Kanenishi K; Ohkawa M
    Ann Nucl Med; 2006 Feb; 20(2):157-60. PubMed ID: 16615426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients].
    Oriuchi N; Higuchi T; Endo K; Tsukamoto N; Matsuda H; Kuji I; Murakami K; Nakajima K
    Kaku Igaku; 2009 Jun; 46(2):96-9. PubMed ID: 19637820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG PET/CT in primary non-Hodgkin's lymphoma of the sinonasal tract.
    Tempescul A; Querellou S; Ianotto JC; Boisramé S; Valette G; Berthou C
    Ann Hematol; 2010 Jun; 89(6):635-7. PubMed ID: 19844711
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.
    Spaepen K; Stroobants S; Dupont P; Vandenberghe P; Thomas J; de Groot T; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    Ann Oncol; 2002 Sep; 13(9):1356-63. PubMed ID: 12196360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. False-positive FDG-PET findings due to bone metastasis from prostate cancer in staging of non-Hodgkin's lymphoma.
    Inoue Y; Tamaki H; Yamagami T; Iwasaki H; Nakatsuka S; Soma T
    Eur J Haematol; 2007 Jul; 79(1):88-90. PubMed ID: 17532762
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.
    Zinzani PL; Gandolfi L; Broccoli A; Argnani L; Fanti S; Pellegrini C; Stefoni V; Derenzini E; Quirini F; Baccarani M
    Cancer; 2011 Mar; 117(5):1010-8. PubMed ID: 20960498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG-PET/CT Pulmonary Infiltrates in Non-Hodgkin Lymphoma Patients Treated with Combined Immunochemotherapy: Incidence and Clinical Characteristics.
    Cohen YC; Berger T; Eshel L; Stern D; Bairey O; Raanani P; Shpilberg O
    Isr Med Assoc J; 2017 Jun; 19(6):372-377. PubMed ID: 28647936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Importance of Bone Marrow Uptake on Baseline
    Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
    Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bilateral primary renal lymphoma in a pediatric patient: staging and response evaluation with ¹⁸F-FDG PET/CT.
    Dhull VS; Mukherjee A; Karunanithi S; Durgapal P; Bal C; Kumar R
    Rev Esp Med Nucl Imagen Mol; 2015; 34(1):49-52. PubMed ID: 25065972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced pneumonitis detected earlier by 18F-FDG-PET than by high-resolution CT: a case report with non-Hodgkin's lymphoma.
    Yamane T; Daimaru O; Ito S; Nagata T; Yoshiya K; Fukaya N; Ito S; Imai T; Uchida H
    Ann Nucl Med; 2008 Oct; 22(8):719-22. PubMed ID: 18982476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
    Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
    J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis.
    Adams HJ; Kwee TC
    Crit Rev Oncol Hematol; 2016 Oct; 106():55-63. PubMed ID: 27637352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
    Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment.
    Herrmann K; Buck AK; Schuster T; Junger A; Wieder HA; Graf N; Ringshausen I; Rudelius M; Wester HJ; Schwaiger M; Keller U; Dechow T
    J Nucl Med; 2011 May; 52(5):690-6. PubMed ID: 21498532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.
    Wu X; Pertovaara H; Korkola P; Vornanen M; Järvenpää R; Dastidar P; Eskola H; Kellokumpu-Lehtinen PL
    Acta Oncol; 2014 Aug; 53(8):1093-9. PubMed ID: 24960581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma.
    Park S; Moon SH; Park LC; Hwang DW; Ji JH; Maeng CH; Cho SH; Ahn HK; Lee JY; Kim SJ; Choi JY; Kim WS
    Am J Hematol; 2012 Sep; 87(9):937-40. PubMed ID: 22730093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.